Original article
Oral fabrol (oral N-acetylcysteine) in chronic bronchitis

https://doi.org/10.1016/0007-0971(87)90182-3Get rights and content

Abstract

Five hundred and twenty-six patients suffering from chronic bronchitis were randomized to receive either N-acetylcysteine (NAC) or placebo during a 6-month period. The aim was to compare the number of acute exacerbations in the two groups. General practitioners were asked to enter patients with a diagnosis of chronic bronchitis, based on the MRC criteria. We failed to find any statistically significant difference in the number of exacerbations between the two treatment groups although there was a slight trend towards improvement in the NAC group during the first 3 months of the trial. The tolerability was similar for both treatments. Patients taking NAC showed a reduction in number of days on which they were incapacitated and this result was statistically significant.

References (10)

  • HMSO

    Socialsecurity statistics

    (1984)
  • C Grassi et al.

    A controlled trial of intermittent oral acetylcysteine in the long term treatment of chronic bronchitis

    Eur. J Clin Pharmac

    (1976)
  • Long term oral acetylcysteine in chronic bronchitis—a double blind controlled study

    Eur J Resp Dis

    (1980)
  • G Boman et al.

    Oral acetylcysteine reduces exacerbation rate in chronic bronchitis

  • British Thoracic Society Research Committee

    Oral N-acetylcysteine exacerbation rates in patients with chronic bronchitis and severe airways obstruction

There are more references available in the full text version of this article.

Cited by (0)

View full text